Insulin Regulates Glucagon-Like Peptide-1 Secretion from the Enteroendocrine L Cell
Open accessThe DOI matches its Crossref record; 73 of the 75 references it cites were found in a registry or an index.
Abstract
Insulin resistance and type 2 diabetes mellitus are associated with impaired postprandial secretion of glucagon-like peptide-1 (GLP-1), a potent insulinotropic hormone. The direct effects of insulin and insulin resistance on the L cell are unknown. We therefore hypothesized that the L cell is responsive to insulin and that insulin resistance impairs GLP-1 secretion. The effects of insulin and insulin resistance were examined in well-characterized L cell models: murine GLUTag, human NCI-H716, and fetal rat intestinal cells. MKR mice, a model of chronic hyperinsulinemia, were used to assess the function of the L cell in vivo. In all cells, insulin activated the phosphatidylinositol 3 kinase-Akt and MAPK kinase (MEK)-ERK1/2 pathways and stimulated GLP-1 secretion by up to 275 ± 58%. Insulin resistance was induced by 24 h pretreatment with 10−7m insulin, causing a marked reduction in activation of Akt and ERK1/2. Furthermore, both insulin-induced GLP-1 release and secretion in response to glucose-dependent insulinotropic peptide and phorbol-12-myristate-13-acetate were significantly attenuated. Whereas inhibition of phosphatidylinositol 3 kinase with LY294002 potentiated insulin-induced GLP-1 release, secretion was abrogated by inhibiting the MEK-ERK1/2 pathway with PD98059 or by overexpression of a kinase-dead MEK1-ERK2 fusion protein. Compared with controls, MKR mice were insulin resistant and displayed significantly higher fasting plasma insulin levels. Furthermore, they had significantly higher basal GLP-1 levels but displayed impaired GLP-1 secretion after an oral glucose challenge. These findings indicate that the intestinal L cell is responsive to insulin and that insulin resistance in vitro and in vivo is associated with impaired GLP-1 secretion. Insulin is a novel secretagogue of the incretin hormone, glucagon-like peptide-1 (GLP-1), and L cell insulin resistance impairs heterologous secretagogue-induced GLP-1 secretion in vitro and in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, GLP-1 and GIP mediate insulin secretion and concomitantly, insulin modulates GIP212 and GLP-1 release; the latter ocurring through the PI3K/Akt- and mitogen-activated protein kinase kinase (MAPKK or MEK)/ERK1/2 pathway.213”
From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [213]
Citations
Cites
1 retracted
Bi-directional Regulation of Brown Fat Adipogenesis by the Insulin Receptor
Entingh, A. J., Taniguchi, C. M., & Kahn, C. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303056200 · Cited by 59 · cited 2×
“Identification of mouse and human insulin receptor transcripts was based on primers and conditions reported to generate PCR products of 500 or 600 (isoform A)/636 (isoform B) bp, respectively (36, 37).”
MethodRetractedThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 6×
“org Endocrinology, February 2009, 150(2):580–591”
BackgroundInfluentialVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 1×
“Given the demonstrated importance of endogenous GLP-1 release to the maintenance of normal insulin secretion and glucose homeostasis (47, 48), it is therefore somewhat paradoxical that postprandial GLP-1 release is decreased in subjects with type 2 diabetes and insulin resistance, independent of obesity (18–24).”
BackgroundSelf-citationGlucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654
Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605
Usdin, T. B., Mezey, E., Button, D. C., Brownstein, M. J., & Bonner, T. I. (1993) · Endocrinology · doi:10.1210/endo.133.6.8243312 · Cited by 534 · cited 1×
“Interestingly, although GIP and PMA stimulate GLP-1 secretion through the activation of protein kinase A and protein kinase C isoenzymes, respectively (9, 70), recent studies demonstrated that these secretagogues can also activate the MEK-ERK1/2 pathway in other cell models (71, 72).”
BackgroundVilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528
Pandini, G., Frasca, F., Mineo, R., Sciacca, L., Vigneri, R., & Belfiore, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202766200 · Cited by 500 · cited 1×
“Identification of mouse and human insulin receptor transcripts was based on primers and conditions reported to generate PCR products of 500 or 600 (isoform A)/636 (isoform B) bp, respectively (36, 37).”
MethodRole of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion
Rocca, A. S., & Brubaker, P. L. (1999) · Endocrinology · doi:10.1210/en.140.4.1687 · Cited by 464
Self-citationVilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444 · cited 1×
“As the rate of clearance of bioactive GLP-1 between normal subjects and those with type 2 diabetes is not different (20), these findings suggest a secretory defect in the L cell.”
BackgroundMuscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409
Gribble, F. M., Williams, L., Simpson, A. K., & Reimann, F. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1147 · Cited by 393
Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes
Fernández, A. M., Kim, J. K., Yakar, S., Dupont, J., Hernandez-Sanchez, C., Castle, A. L., Filmore, J., Shulman, G. I., & Le Roith, D. (2001) · Genes & Development · doi:10.1101/gad.908001 · Cited by 369 · cited 3×
“Additionally, nonobese, insulin-resistant MKR mice were used to examine the effects of chronic hyperinsulinemia on GLP-1 secretion from the enteroendocrine L cell in vivo (26, 27).”
BackgroundEdwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · cited 1×
“Given the demonstrated importance of endogenous GLP-1 release to the maintenance of normal insulin secretion and glucose homeostasis (47, 48), it is therefore somewhat paradoxical that postprandial GLP-1 release is decreased in subjects with type 2 diabetes and insulin resistance, independent of obesity (18–24).”
BackgroundRobinson, M. J., Stippec, S. A., Goldsmith, E., White, M. A., & Cobb, M. H. (1998) · Current Biology · doi:10.1016/s0960-9822(07)00485-x · Cited by 311 · cited 3×
“Recombinant adenoviruses expressing green fluorescent protein (GFP) or a dominant-negative form of ERK-2 (Ad-MEK1-ERK2 KR) (40) were generated and purified as previously described (41, 42).”
BackgroundMethodResultRoberge, J. N. (1993) · Endocrinology · doi:10.1210/en.133.1.233 · Cited by 276
Self-citationRole of Leptin in the Regulation of Glucagon-Like Peptide-1 Secretion
Anini, Y., & Brubaker, P. L. (2003) · Diabetes · doi:10.2337/diabetes.52.2.252 · Cited by 276 · cited 8×
“The mouse L cell model, GLUTag, was generated from a large bowel tumor in mice carrying a proglucagon/simian virus 40 large T-antigen transgene, whereas human NCI-H716 L cells were derived from a poorly differentiated adenocarcinoma of the cecum (9, 14, 15).”
BackgroundMethodSelf-citationMcLaughlin, T., Abbasi, F., Lamendola, C., Frayo, R. S., & Cummings, D. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031572 · Cited by 274 · cited 1×
“The notion that impaired insulin action reduces secretion by the endocrine intestine is not without precedence because release of the orexigenic hormone, ghrelin, is also decreased in nonobese subjects with insulin resistance (25).”
BackgroundTotal insulin and IGF-I resistance in pancreatic β cells causes overt diabetes
Ueki, K., Okada, T., Hu, J., Liew, C. W., Assmann, A., Dahlgren, G. M., Peters, J. L., Shackman, J. G., Zhang, M., Artner, I., et al. (2006) · Nature Genetics · doi:10.1038/ng1787 · Cited by 257
Rask, E., Olsson, T., Söderberg, S., Johnson, O., Seckl, J., Holst, J. J., & Ahrén, B. (2001) · Diabetes Care · doi:10.2337/diacare.24.9.1640 · Cited by 229 · cited 2×
“(23, 24) demonstrated in a cohort of normal male subjects with varying degrees of insulin sensitivity that insulin resistance is negatively correlated with GLP-1 secretion.”
BackgroundResultGlucagon-Like Peptide 1 Secretion by the L-Cell
Lim, G. E., & Brubaker, P. L. (2006) · Diabetes · doi:10.2337/db06-s020 · Cited by 223 · cited 13×
“GIP, used as a positive control for the rodent L cell (1), increased GLP-1 secretion to 286.”
BackgroundMethodSelf-citationYi, F., Sun, J., Lim, G. E., Fantus, I. G., Brubaker, P. L., & Jin, T. (2008) · Endocrinology · doi:10.1210/en.2007-1142 · Cited by 167 · cited 1×
“Insulin has also been reported to stimulate proglucagon gene expression, as well as GLP-1 synthesis, in GLUTag cells through an Akt-glycogen synthase kinase-3 pathway that involves the bipartite transcription factor, T cell transcription factor-4 (49).”
BackgroundSelf-citationLingohr, M. K., Dickson, L. M., McCuaig, J. F., Hügl, S., Twardzik, D. R., & Rhodes, C. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.966 · Cited by 165 · cited 1×
“Recombinant adenoviruses expressing green fluorescent protein (GFP) or a dominant-negative form of ERK-2 (Ad-MEK1-ERK2 KR) (40) were generated and purified as previously described (41, 42).”
MethodSelf-citationDevelopment of Insulin Resistance in 3T3-L1 Adipocytes
Thomson, M. J., Williams, M. G., & Frost, S. C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.12.7759 · Cited by 164
Anini, Y. (2002) · Endocrinology · doi:10.1210/en.143.6.2420 · Cited by 161 · cited 1×
“Fetal rat intestinal cell (FRIC) cultures are a heterogeneous primary L cell model, cultured from fetal intestines collected from term pregnant Wistar rats, as previously described in detail (6, 9, 13, 15).”
MethodSelf-citationTomas, A., Yermen, B., Min, L., Pessin, J. E., & Halban, P. A. (2006) · Journal of Cell Science · doi:10.1242/jcs.02942 · Cited by 161 · cited 1×
“MEK-ERK1/2 signaling has also been found to play a role in the release of other hormones, including insulin (59, 60) and the catecholamines (61, 62); moreover, an essential role for this pathway in the human L cell has been demonstrated for meat hydrolysate- and amino acid-induced GLP-1 secretion (63).”
BackgroundRegulation of Intestinal Proglucagon- Derived Peptide Secretion by Intestinal Regulatory Peptides*
BRUBAKER, P. L. (1991) · Endocrinology · doi:10.1210/endo-128-6-3175 · Cited by 159
Self-citationLi, G., Barrett, E. J., Wang, H., Chai, W., & Liu, Z. (2005) · Endocrinology · doi:10.1210/en.2005-0505 · Cited by 152
Roberge, J. N., Gronau, K. A., & Brubaker, P. L. (1996) · Endocrinology · doi:10.1210/endo.137.6.8641190 · Cited by 142
Self-citationMuscarinic Receptors Control Glucagon-Like Peptide 1 Secretion by Human Endocrine L Cells
Anini, Y., & Brubaker, P. L. (2003) · Endocrinology · doi:10.1210/en.2003-0143 · Cited by 141 · cited 4×
“Asa, University of Toronto, Toronto, Ontario, Canada), and all cell models were subjected to immunohistochemistry or -cytochemistry, as previously described (9, 14, 15, 35).”
MethodSelf-citationHuang, C., Somwar, R., Patel, N., Niu, W., Török, D., & Klip, A. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2090 · Cited by 135
Ehses, J. A., Pelech, S. L., Pederson, R. A., & McIntosh, C. H. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205055200 · Cited by 133 · cited 1×
“Interestingly, although GIP and PMA stimulate GLP-1 secretion through the activation of protein kinase A and protein kinase C isoenzymes, respectively (9, 70), recent studies demonstrated that these secretagogues can also activate the MEK-ERK1/2 pathway in other cell models (71, 72).”
BackgroundLonguet, C., Broca, C., Costes, S., Hani, E. H., BATAILLE, D., & Dalle, S. (2004) · Endocrinology · doi:10.1210/en.2004-0841 · Cited by 132 · cited 1×
“MEK-ERK1/2 signaling has also been found to play a role in the release of other hormones, including insulin (59, 60) and the catecholamines (61, 62); moreover, an essential role for this pathway in the human L cell has been demonstrated for meat hydrolysate- and amino acid-induced GLP-1 secretion (63).”
BackgroundFederico, L. M., Naples, M., Taylor, D., & Adeli, K. (2006) · Diabetes · doi:10.2337/db04-1084 · Cited by 132 · cited 1×
“The expression of the insulin receptor throughout the intestine is not surprising because insulin has been found to regulate lipoprotein synthesis from enterocytes (43).”
BackgroundDickson, L. M., Lingohr, M. K., McCuaig, J. F., Hügl, S., Snow, L., Kahn, B. B., Myers, M. G., & Rhodes, C. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101257200 · Cited by 128 · cited 1×
“Recombinant adenoviruses expressing green fluorescent protein (GFP) or a dominant-negative form of ERK-2 (Ad-MEK1-ERK2 KR) (40) were generated and purified as previously described (41, 42).”
MethodSelf-citationGLP-1 does not acutely affect insulin sensitivity in healthy man
Ørskov, L., Holst, J. J., Møller, J., Ørskov, C., Møller, N., Alberti, K. G. M. M., & Schmitz, O. (1996) · Diabetologia · doi:10.1007/bf02658511 · Cited by 123
Pirola, L., Bonnafous, S., Johnston, A., Chaussade, C., Portis, F., & OBBERGHEN, E. V. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208984200 · Cited by 121
Rocca, A. S. (1995) · Endocrinology · doi:10.1210/en.136.12.5593 · Cited by 117 · cited 2×
“IGF-1 (10x M) * * C (1) (2) (3) (4) (5) (6) Mouse Human”
MethodSelf-citationImmunocytochemical Detection of Phosphatidylinositol 3-kinase Activation by Insulin and Leptin
Niswender, K. D., Gallis, B., Blevins, J. E., Corson, M. A., Schwartz, M. W., & Baskin, D. G. (2003) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540305100302 · Cited by 116 · cited 1×
“Asa, University of Toronto, Toronto, Ontario, Canada), and all cell models were subjected to immunohistochemistry or -cytochemistry, as previously described (9, 14, 15, 35).”
MethodReimer, R. A. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06557 · Cited by 115 · cited 1×
“MEK-ERK1/2 signaling has also been found to play a role in the release of other hormones, including insulin (59, 60) and the catecholamines (61, 62); moreover, an essential role for this pathway in the human L cell has been demonstrated for meat hydrolysate- and amino acid-induced GLP-1 secretion (63).”
BackgroundIakoubov, R., Izzo, A. A., Yeung, A., Whiteside, C. I., & Brubaker, P. L. (2006) · Endocrinology · doi:10.1210/en.2006-1403 · Cited by 114 · cited 14×
“The mouse L cell model, GLUTag, was generated from a large bowel tumor in mice carrying a proglucagon/simian virus 40 large T-antigen transgene, whereas human NCI-H716 L cells were derived from a poorly differentiated adenocarcinoma of the cecum (9, 14, 15).”
BackgroundMethodSelf-citationDuodenal Leptin Stimulates Cholecystokinin Secretion
Guilmeau, S., Buyse, M., Tsocas, A., Laigneau, J. P., & Bado, A. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1664 · Cited by 112
Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Fanelli, A., Messeri, G., & Rotella, C. M. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00367.x · Cited by 106
Rask, E., Olsson, T., Söderberg, S., Holst, J. J., Tura, A., Pacini, G., & Åhrén, B. (2004) · Metabolism · doi:10.1016/j.metabol.2003.11.011 · Cited by 99
Hansen, L., Hartmann, B., Mineo, H., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.021 · Cited by 93
Sidhu, S., Thompson, D. G., Warhurst, G., CASE, R. M., & Benson, R. (2000) · The Journal of Physiology · doi:10.1111/j.1469-7793.2000.00165.x · Cited by 88
Ryan, A. S., Egan, J. M., Habener, J. F., & Elahi, D. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4988 · Cited by 84
Asghar, Z., Yau, D., Chan, F., LeRoith, D., Chan, C. B., & Wheeler, M. B. (2005) · Diabetologia · doi:10.1007/s00125-005-0045-y · Cited by 79
Self-citationEl‐Kholy, W., Macdonald, P. E., Lin, J., Wang, J., Fox, J. M., Light, P. E., Wang, Q., Tsushima, R. G., & Wheeler, M. B. (2003) · The FASEB Journal · doi:10.1096/fj.02-0802fje · Cited by 77 · cited 1×
“GLP-1 release in either of the L cell lines but instead potentiated both basal and insulin-induced GLP-1 secretion, possibly due to nonspecific effects (64).”
BackgroundPersson, K., Gingerich, R. L., Nayak, S., Wada, K., Wada, E., & Ahrén, B. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.5.e956 · Cited by 72
Mulligan, C., Rochford, J. J., Denyer, G. S., Stephens, R., Yeo, G. S. H., Freeman, T., Siddle, K., & O’Rahilly, S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206206200 · Cited by 66
Ryan, A. S. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.7.2399 · Cited by 65
Benes, C. H., Poitout, V., Marie, J., Martı́n-Pérez, J., Roisin, M. P., & Fagard, R. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3400219 · Cited by 64 · cited 1×
“Interestingly, although GIP and PMA stimulate GLP-1 secretion through the activation of protein kinase A and protein kinase C isoenzymes, respectively (9, 70), recent studies demonstrated that these secretagogues can also activate the MEK-ERK1/2 pathway in other cell models (71, 72).”
BackgroundKusari, A. B. (1997) · Molecular Endocrinology · doi:10.1210/me.11.10.1532 · Cited by 61 · cited 1×
“Decreased insulin-mediated GLP-1 secretion in insulin resistance may be partly explained by the down-regulation observed in MEK-ERK1/2 activation, as seen with decreased ERK1/2 phosphorylation,possibly inassociationwithknowneffectsof insulin to up-regulate the expression and activity of dual-specificity MAPK phosphata…”
BackgroundCreutzfeldt, W., Talaulicar, M., Ebert, R., & Willms, B. (1980) · Diabetes · doi:10.2337/diab.29.2.140 · Cited by 50
Xu, H., Yang, Q., Shen, M., Huang, X., Dembski, M., Gimeno, R. E., Tartaglia, L. A., Kapeller, R., & Wu, Z. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508027200 · Cited by 49 · cited 1×
“Decreased insulin-mediated GLP-1 secretion in insulin resistance may be partly explained by the down-regulation observed in MEK-ERK1/2 activation, as seen with decreased ERK1/2 phosphorylation,possibly inassociationwithknowneffectsof insulin to up-regulate the expression and activity of dual-specificity MAPK phosphata…”
BackgroundCox, M., Ely, C. M., Catling, A. D., Weber, M. J., & Parsons, S. J. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66031103.x · Cited by 46 · cited 1×
“MEK-ERK1/2 signaling has also been found to play a role in the release of other hormones, including insulin (59, 60) and the catecholamines (61, 62); moreover, an essential role for this pathway in the human L cell has been demonstrated for meat hydrolysate- and amino acid-induced GLP-1 secretion (63).”
BackgroundAït‐Ali, D., Turquier, V., Grumolato, L., Yon, L., Jourdain, M., Alexandre, D., Eiden, L. E., Vaudry, H., & Anouar, Y. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0129 · Cited by 46 · cited 1×
“MEK-ERK1/2 signaling has also been found to play a role in the release of other hormones, including insulin (59, 60) and the catecholamines (61, 62); moreover, an essential role for this pathway in the human L cell has been demonstrated for meat hydrolysate- and amino acid-induced GLP-1 secretion (63).”
BackgroundTang, S., Le‐Tien, H., Goldstein, B. J., Shin, P., Lai, R., & Fantus, I. G. (2001) · Diabetes · doi:10.2337/diabetes.50.1.83 · Cited by 45
Monti, S., Di Silverio, F., Iraci, R., Martini, C., Lanzara, S., Falasca, P., Poggi, M., Stigliano, A., Sciarra, F., & Toscano, V. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7413 · Cited by 40 · cited 1×
“Primers used to amplify IGF-I receptor mRNA transcripts in mouse and human RNA samples generated PCR products of 71 and 300 bp, respectively (38, 39).”
BackgroundKalloo-Hosein, H. E., Whitehead, J. P., Soos, M. A., Tavaré, J. M., Siddle, K., & O’Rahilly, S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24325 · Cited by 37
Brubaker, P. L., Efendic, S., & Greenberg, G. R. (1997) · Endocrine · doi:10.1007/bf02738808 · Cited by 36
Self-citationBaudry, A., Lamothe, B., Bucchini, D., Jami, J., Montarras, D., Pinset, C., & Joshi, R. L. (2001) · FEBS Letters · doi:10.1016/s0014-5793(00)02435-2 · Cited by 35
Regulation of Peptide-YY Synthesis and Secretion in Fetal Rat Intestinal Cultures*
BRUBAKERt, P. L., Drucker, D. J., Asa, S. L., & Greenberg, G. R. (1991) · Endocrinology · doi:10.1210/endo-129-6-3351 · Cited by 32
Bryer‐Ash, M., Cheung, A. P., & Pederson, R. A. (1994) · Regulatory Peptides · doi:10.1016/0167-0115(94)90199-6 · Cited by 32 · cited 1×
“Finally, whereas other studies demonstrated that insulin inhibits GIP secretion during conditions of euglycemia, this inhibitory effect is reversed when blood glucose levels are elevated, suggesting either a loss of the inhibitory effect of insulin on GIP release or a possible stimulatory effect of insulin on the K ce…”
ResultGallwitz, B. (2005) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2005.7.651 · Cited by 26 · cited 3×
“D’Alessio, University of Cincinnati, Cincinnati, OH), the - or -subunits of the insulin receptor (rabbit antimouse; Santa Cruz Biotechnology, Santa Cruz, CA), or phosphatidylinositol-(3,4,5)-phosphate (PIP3; mouse anti-PIP3; Echelon Biosciences, Salt Lake City, UT).”
BackgroundAmoui, M., Craddock, B., & Miller, W. T. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1710153 · Cited by 23
Furman, B. L., & Pyne, N. J. (2006) · PubMed · Cited by 20
Synthesis and secretion of somatostatin-28 and -14 by fetal rat intestinal cells in culture
BRUBAKER, P. L., Drucker, D. J., & Greenberg, G. R. (1990) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1990.258.6.g974 · Cited by 18
Self-citationSerial analysis of gene expression in murine fetal thymocyte cell lines
Zhao, F. (2002) · International Immunology · doi:10.1093/intimm/dxf103 · Cited by 8 · cited 1×
“Primers used to amplify IGF-I receptor mRNA transcripts in mouse and human RNA samples generated PCR products of 71 and 300 bp, respectively (38, 39).”
From cradle to grave: pancreatic beta-cell mass and glucagon-like peptide-1.
Wong, V. S. C., & BRUBAKER, P. L. (2006) · PubMed · Cited by 7
Self-citation
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
The Impact of Food Bioactives on Health
(2015) · Springer eBooks · doi:10.1007/978-3-319-16104-4 · Cited by 805
Młynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031094 · Cited by 328
“…other tissues and organs, including the stomach by delaying gastric emptying, the heart by exerting cardioprotective effects, and adipose tissue and skeletal muscle by improving glucose uptake, and it also acts centrally on neurons in the hypothalamus, inducing a feeling of satiety [99–101].”
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251
“As a parallel to the insulin resistance-associated hyperinsulinaemic state in the early stages of type 2 diabetes (followed by insulin hyposecretion in the later stages), we hypothesise that compensatory L cell secretion of GLP-1 may exist in the early stages of type 2 diabetes, followed by L cell ‘exhaustion’ when th…”
Metadata
- Authors
- Lim, G. E., Huang, G. J., Flora, N., LeRoith, D., Rhodes, C. J., & Brubaker, P. L.
- Affiliations
- University of Toronto (CA)
- Icahn School of Medicine at Mount Sinai (US)
- University of Chicago (US)
- Corresponding author
- Brubaker, Patricia L.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2009-02-01
- Volume
- 150
- Issue
- 2
- Pages
- 580-591
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC5393261
- OpenAlex
- W2010671489
- Cited by
- 200
- References
- 75
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 9 · 2023: 12 · 2022: 5 · 2021: 25 · 2020: 8 · 2019: 12 · 2018: 10 · 2017: 14 · 2016: 12 · 2015: 17 · 2014: 11 · 2013: 14 · 2012: 12
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrinology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK050610, R01DK055267)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- insulin, glucagon-like peptide-1, enteroendocrine L cells, insulin resistance, type 2 diabetes, phosphatidylinositol 3-kinase, Akt signaling, MEK/ERK1/2 pathway, GLP-1 secretion, hyperinsulinemia, glucose-dependent insulinotropic polypeptide, intestinal hormone secretion
- MeSH terms
- Animals, Cells, Cultured, Female, Humans, Insulin, Insulin Resistance, Insulin-Like Growth Factor I, Male, Pregnancy, Receptor, Insulin, Signal Transduction, Rats, Wistar, Receptor, IGF Type 1, Mice, Knockout, Enteroendocrine Cells, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.